Atara Biotherapeutics, Inc. (ATRA): history, ownership, mission, how it works & makes money

A Brief History of Atara Biotherapeutics, Inc. (ATRA)

Company Formation and Early Years

Atara Biotherapeutics, Inc. was founded in 2012 in San Diego, California. The company was established to focus on developing off-the-shelf T-cell immunotherapies for cancer and other viral diseases, leveraging technology from the field of adaptive cellular immunotherapy.

Initial Public Offering (IPO)

In June 2014, Atara Biotherapeutics went public, pricing its initial public offering at $12 per share. The IPO raised approximately $84 million and allowed the company to expand its research and development efforts.

Key Product Developments

• ATA188: In 2018, the company initiated a clinical trial for ATA188, an investigational T-cell therapy targeting EBV+ multiple sclerosis.
• ATA3219: In the same year, Atara began studies for ATA3219, aimed at treating patients with advanced cancers.

Financial Performance

As of Q2 2023, Atara Biotherapeutics reported cash and cash equivalents of approximately $153 million, which is expected to extend the company’s runway into the second half of 2024. The total revenue for the fiscal year 2022 was recorded at $14.6 million.

Collaborations and Partnerships

Atara has engaged in significant partnerships to advance its therapeutic pipeline. Some notable collaborations include:

• Partnership with Bayer: Announced in 2021, this partnership focuses on the development and commercialization of Atara's T-cell therapies.
• Collaboration with the University of Pennsylvania: This collaboration aims to enhance research efforts in cellular therapies.

Clinical Trials and Regulatory Milestones

Atara Biotherapeutics has been involved in multiple clinical trials for its key product candidates:

Recent Developments

In August 2023, Atara Biotherapeutics announced the completion of its Phase 1 clinical trial for ATA3219, demonstrating a favorable safety profile and encouraging preliminary efficacy in patients.

Market Position and Future Prospects

As of October 2023, Atara Biotherapeutics has a market capitalization of approximately $446 million. The company continues to focus on its pipeline and partnerships as it navigates the competitive landscape of biotherapeutics.

A Who Owns Atara Biotherapeutics, Inc. (ATRA)

Ownership Structure

Atara Biotherapeutics, Inc. (NASDAQ: ATRA) has a diverse ownership structure comprising institutional investors, individual shareholders, and company insiders. As of the latest available data, the following breakdown illustrates the major shareholders:

Major Institutional Shareholders

The institutional investors play a significant role in Atara Biotherapeutics' ownership. The following table lists the top institutions holding shares in ATRA:

Insider Ownership

Insider ownership is a critical aspect of Atara’s governance. Notable company executives and board members hold a significant stake in the firm. Below is a summary of the top insiders and their respective ownership:

Recent Developments Impacting Ownership

Atara Biotherapeutics has seen fluctuations in its ownership due to recent financial events, including capital raises and stock price changes. The company reported a market capitalization of approximately $350 million as of the last trading session. The stock price has experienced volatility, with a 52-week range of $1.50 to $6.50.

Stock Performance Overview

The following table summarizes ATRA’s stock performance over recent months:

Conclusion on Ownership Dynamics

Ownership dynamics at Atara Biotherapeutics reflect a robust institutional backing alongside committed insider participation. The shifts in stock performance, market conditions, and institutional strategies will play a crucial role in shaping future ownership structures and shareholder relations.

Atara Biotherapeutics, Inc. (ATRA) Mission Statement

Corporate Vision

Atara Biotherapeutics, Inc. is focused on pioneering the development of innovative allogeneic T-cell therapies for patients with serious illnesses, particularly in the field of oncology and autoimmune diseases. The company aims to deliver transformative therapies that leverage its proprietary T-cell platform, aiming to improve the lives of patients suffering from diseases like cancer and multiple sclerosis.

Targeted Therapies

The company's mission statement emphasizes the commitment to providing targeted treatments that are not only effective but also accessible. Atara aims to enhance patient outcomes through precision medicine, tailoring therapies to meet the unique needs of individuals.

Commitment to Innovation

Atara's focus on research and development is evident in its strategic initiatives. In 2021, Atara announced an increase in R&D spending to approximately $140 million, reflecting its dedication to advancing its pipeline of therapies. The company's goal is to leverage its expertise in cellular therapy to develop novel solutions that address unmet medical needs.

Financial Overview

As of Q2 2023, Atara Biotherapeutics reported total revenues of approximately $6.8 million, primarily generated from collaborations and grants. The company reported a net loss of $24.5 million during the same period, which underlines the significant investment in R&D and operational expenses.

Pipeline Development

Atara’s pipeline includes several key assets, including:

• ATA188 for the treatment of multiple sclerosis, currently in Phase 2 clinical trials.
• ATA3219 for the treatment of Epstein-Barr virus-associated malignancies, also in Phase 2 clinical trials.
• ATA2271 for solid tumors, in early clinical development stages.

Partnerships and Collaborations

The company actively seeks partnerships to bolster its mission. As of mid-2023, Atara has established collaborations with organizations such as:

• Merck KGaA for global commercialization.
• Gilead Sciences for co-development of T-cell therapies.

Market Capitalization

As of September 2023, Atara Biotherapeutics’ market capitalization stood around $400 million. This figure reflects the company’s position in the biopharmaceutical sector and its potential for growth based on its innovative pipeline.

Employee Commitment

Atara recognizes that its workforce is critical to its mission. The company has approximately 200 employees as of 2023, emphasizing a culture of innovation, collaboration, and patient-centric focus.

Company Values

The core values that drive Atara's mission include:

• Integrity: Ensuring ethical practices in all operations.
• Collaboration: Working together with various stakeholders.
• Innovation: Pushing boundaries in therapeutic development.
• Patient Focus: Centering efforts around patient needs and outcomes.

Global Reach

Atara's mission extends beyond the United States. The company is focused on expanding its footprint internationally, working with regulatory bodies to ensure that therapies are accessible to patients worldwide. The global market for cell therapies is projected to reach approximately $30 billion by 2030, representing a significant opportunity for growth.

How Atara Biotherapeutics, Inc. (ATRA) Works

Company Overview

Atara Biotherapeutics, Inc. is a publicly traded biotechnology company focused on developing off-the-shelf T cell immunotherapy for patients with cancer and other serious diseases. As of September 30, 2023, the market capitalization of Atara Biotherapeutics is approximately $290 million.

Research and Development

Atara's primary research revolves around its own proprietary Epstein-Barr Virus (EBV) T cell platform. This platform uses T cells that are engineered to target EBV. The company has several clinical-stage product candidates, including:

• ATA188 for the treatment of multiple sclerosis
• ATA3219 for patients with Epstein-Barr Virus-associated malignancies

Clinical Trials

Atara Biotherapeutics has been engaged in various clinical trials to evaluate the efficacy of its product candidates. As of 2023, the company has reported:

• Phase 2 clinical trials for ATA188 with over 60 patients enrolled.
• Phase 1 trials for ATA3219, which began in 2021.

The total estimated cost for the ongoing trials is approximately $75 million.

Financial Performance

For the third quarter of 2023, Atara Biotherapeutics reported:

• Total revenues of $10 million
• Net loss of $24 million
• Cash and cash equivalents of $150 million

In the fiscal year ending December 31, 2022, the company reported total revenues of $40 million with a net loss of $120 million.

Stock Performance

As of October 2023, Atara’s stock (ATRA) is trading at approximately $3.65 per share, with a year-to-date decline of about 10%. The 52-week range of the stock price is from $2.85 to $5.25.

Partnerships and Collaborations

Atara has established several partnerships for advancing its therapies, including:

• Collaboration with Bayer AG for the development of T cell therapies.
• Exclusive licensing agreement with the University of Pennsylvania for access to CAR T technology.

Financial Projections

In its latest financial guidance, Atara Biotherapeutics expects:

• Revenue growth of 15% annually.
• Projected total expenses for 2024 around $100 million.

Table: Key Financial Data

Future Outlook

Looking ahead, Atara Biotherapeutics aims to enhance its clinical development pipeline and expand its product offerings in the T cell immunotherapy space. The focus remains on increasing collaboration opportunities and optimizing operational efficiencies to achieve profitability by 2025.

How Atara Biotherapeutics, Inc. (ATRA) Makes Money

Revenue Streams

Atara Biotherapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The key aspects include:

• Partnerships and Collaborations
• Product Sales
• Licensing Agreements

Partnerships and Collaborations

Atara has partnered with various pharmaceutical companies to develop its therapies. As of the latest available data:

• Partnership with Amgen for the development of ATA188 led to a financial arrangement including up to $80 million in milestone payments.
• Collaboration with U.S. Army for a CAR-T cell therapy targeting EBV has funding of $12 million.

Product Sales

As of Q3 2023, Atara has not yet commercialized any products, but it plans to launch its product candidates in the future, which could significantly contribute to revenue. Estimated market potential for Atara’s lead product, ATA188, is projected to reach $1 billion annually if approved.

Licensing Agreements

Licensing plays a crucial role in Atara's strategy. Recent agreements include:

• A licensing deal for ATA129 with a potential upfront payment of $25 million and royalties.
• Agreements for intellectual property related to T-cell therapies valued at approximately $30 million.

Financial Performance Metrics

As of Q3 2023, Atara reported financial metrics that highlight its operational costs and cash position:

Research and Development Investments

Investment in R&D is critical to Atara’s success, which for FY 2023, stood at approximately $70 million, directed towards:

• Clinical trials for ATA188
• Preclinical studies for ATA129
• Manufacturing process enhancements

Market Opportunities

Atara focuses on unmet medical needs, particularly in oncology and autoimmune diseases. The projected market sizes for key therapeutic segments are:

Future Growth Strategy

Atara aims to enhance its revenue through:

• Continued clinical development of lead products
• Expansion of partnerships
• Exploration of new market segments

Investor Relations

As of Q3 2023, Atara’s stock price is approximately $8.50 per share, with a market capitalization of about $500 million. The company continues to attract investor interest due to its innovative approach and potential breakthroughs in treatment options.